NSE / BSEHealthcare
β‚Ή797.35-2.60-0.33%
P/E87.7Mkt Capβ‚Ή24.92 K CrEV/EBITDA65.6

Krishna Institute of Medical Sciences Limited

P/E87.7Mkt Capβ‚Ή24.92 K CrEV/EBITDA65.6
Company Profile

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers neurology, neurosurgery, psychiatry, and neuro rehabilitation; cardiology, cardiac and vascular surgery, heart transplant, and cardio rehabilitation; and pulmonology, interventional pulmonology, thoracic surgery, and lung transplant. It also provides medical and surgical gastroenterology, hepatobiliary pancreatic surgery, liver transplant, and bariatric surgery; ear, nose, throat, and head and neck surgery; and nephrology, urology, andrology, renal transplant, gynecology, urogynecology, IVF and art, fetal medicine, and obstetrics. In addition, the company offers orthopedics, arthroscopic and spine surgery, and ortho rehabilitation; medical surgical and radiation, and BMT and hematology; ophthalmology; dermatology, cosmetology, and plastic and reconstructive surgery; and clinical infectious diseases. Further, it provides imaging and interventional radiology; paediatrics and pediatric sub specialities, and neonatology; maxillo-facial surgery; OT and day care anaesthesia and pain medicine; and pathology, microbiology, and biochemistry. Additionally, the company offers molecular biology and clinical hematology; internal medicine, general surgery, and diabetology and endocrinology; and ICU, CTICU, SICU, NICU, PICU, neuro and ECMO ICU, and post transplant ICU services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 3.42% over 1Y
Monthly Returns

Historically, Jul has averaged the highest return (+8.7%); Oct the lowest (-2.8%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-0.6%Neutral MonthJan 2026: -0.57%+23.9%Positive MonthFeb 2026: +23.86%-16.7%Negative MonthMar 2026: -16.74%+7.0%Positive MonthApr 2026: +6.99%+14.7%Positive MonthMay 2026: +14.71%+6.5%Positive MonthJun 2026: +6.53%-2.0%*Negative MonthJul 2026: -2.04%β€”β€”β€”β€”β€”
2025+1.5%Neutral MonthJan 2025: +1.50%-14.4%Negative MonthFeb 2025: -14.41%+22.8%Positive MonthMar 2025: +22.82%+2.8%Positive MonthApr 2025: +2.82%+4.1%Positive MonthMay 2025: +4.06%-1.5%Neutral MonthJun 2025: -1.55%+11.4%Positive MonthJul 2025: +11.42%-3.4%Negative MonthAug 2025: -3.36%-3.5%Negative MonthSep 2025: -3.50%+3.1%Positive MonthOct 2025: +3.09%-5.0%Negative MonthNov 2025: -5.02%-11.4%Negative MonthDec 2025: -11.40%
2024+8.2%Positive MonthJan 2024: +8.21%+5.4%Positive MonthFeb 2024: +5.36%-8.7%Negative MonthMar 2024: -8.72%-1.3%Neutral MonthApr 2024: -1.30%-10.1%Negative MonthMay 2024: -10.07%+14.1%Positive MonthJun 2024: +14.06%+3.1%Positive MonthJul 2024: +3.14%+17.7%Positive MonthAug 2024: +17.66%+10.2%Positive MonthSep 2024: +10.17%-2.3%Negative MonthOct 2024: -2.27%+8.8%Positive MonthNov 2024: +8.82%+1.1%Neutral MonthDec 2024: +1.11%
2023-3.8%Negative MonthJan 2023: -3.80%-9.8%Negative MonthFeb 2023: -9.79%+4.8%Positive MonthMar 2023: +4.81%+7.5%Positive MonthApr 2023: +7.53%+6.2%Positive MonthMay 2023: +6.18%+11.1%Positive MonthJun 2023: +11.09%+7.3%Positive MonthJul 2023: +7.35%+4.3%Positive MonthAug 2023: +4.27%-0.9%Neutral MonthSep 2023: -0.88%-4.5%Negative MonthOct 2023: -4.52%+3.5%Positive MonthNov 2023: +3.45%+1.2%Neutral MonthDec 2023: +1.18%
2022-5.7%Negative MonthJan 2022: -5.67%-5.6%Negative MonthFeb 2022: -5.56%+8.7%Positive MonthMar 2022: +8.74%-3.0%Negative MonthApr 2022: -3.01%-1.3%Neutral MonthMay 2022: -1.28%-10.4%Negative MonthJun 2022: -10.40%+4.8%Positive MonthJul 2022: +4.85%-3.1%Negative MonthAug 2022: -3.09%+25.7%Positive MonthSep 2022: +25.73%-1.7%Neutral MonthOct 2022: -1.70%+0.6%Neutral MonthNov 2022: +0.64%+3.3%Positive MonthDec 2022: +3.33%
2021β€”β€”β€”β€”β€”β€”+27.2%Positive MonthJul 2021: +27.24%+6.7%Positive MonthAug 2021: +6.72%-4.9%Negative MonthSep 2021: -4.95%-8.7%Negative MonthOct 2021: -8.67%+9.6%Positive MonthNov 2021: +9.58%+16.5%Positive MonthDec 2021: +16.49%
AvgΒ±SD-0.1%Β±4.8%-0.1%Β±13.7%+2.2%Β±13.8%+2.6%Β±4.2%+2.7%Β±8.2%+3.9%Β±8.9%+8.7%Β±9.3%+4.4%Β±7.7%+5.3%Β±11.5%-2.8%Β±3.8%+3.5%Β±5.4%+2.1%Β±8.9%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.313x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή1.38 K Crβ–² 13.3%
EBITDA Growthβ€”
Net Profitβ‚Ή303.00 Crβ–² 28.9%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 133.3%
Revenue CAGR 5Y9.1%
EBITDA CAGR 5Y12.5%
Net Profit CAGR 5Y14.2%
NP Growth 1Y28.9%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή1.38 K Crβ€”β‚Ή303.00 Crβ€”β€”14.0%13.3%28.9%
Mar 2024β‚Ή1.22 K Crβ€”β‚Ή235.00 Crβ€”β€”12.6%8.0%-6.7%
Mar 2023β‚Ή1.13 K Crβ€”β‚Ή252.00 Crβ€”β€”15.5%-1.0%-9.4%
Mar 2022β‚Ή1.14 K Crβ€”β‚Ή278.00 Crβ€”β€”20.2%22.5%47.1%
Mar 2021β‚Ή933.00 Crβ€”β‚Ή189.00 Crβ€”β€”20.8%18.1%56.2%
Mar 2020β‚Ή790.00 Crβ€”β‚Ή121.00 Crβ€”β€”19.4%11.7%-375.0%
Mar 2019β‚Ή707.00 Crβ€”β‚Ή-44.00β€”β€”-8.7%12.6%-45.7%
Mar 2018β‚Ή628.00 Crβ€”β‚Ή-81.00β€”β€”40.7%17.2%-345.5%
Mar 2017β‚Ή536.00 Crβ€”β‚Ή33.00 Crβ€”β€”10.2%10.5%37.5%
Mar 2016β‚Ή485.00 Crβ€”β‚Ή24.00 Crβ€”β€”9.2%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales4855366287077909331,1431,1321,2221,3841,497
Total Expenses3804225626525846247407688579631,076
EBIT / Operating Profit1041146655206309403364366421421
OPM %22%21%10%8%26%33%35%32%30%30%28%
Other Income4336782123186880
Finance Costs3632883324189572845
Depreciation & Amortisation3434384143454545585868
Profit Before Tax3851-57-13147254371337318403388
Tax %37%37%43%225%17%26%25%25%26%25%-
Net Profit / PAT2433-81-44121189278252235303292
EPS (β‚Ή)0.690.91-2.27-1.173.254.866.966.315.887.577.31
Dividend Payout %0%0%0%0%0%0%0%0%0%0%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Krishna Institute of Medical Sciences Limitedthis co.β‚Ή24.92 K Crβ‚Ή1.38 K Cr87.7010.8965.5513.3%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Krishna Institute of Medical Sciences Limited and the metrics that matter.

Browse the full Equiscale Academy